We talk about the recent market turmoil and how that will impact investor actions. Will investors stick to their guns or succumb and sell if the market continues to sell off. A few comments on Medtronic’s settlement and how insurance could have been implemented to reduce the financial burden for Medtronic.
GE has seen its market cap decrease by over $200B since 2016 and it now trades at around $8. Is this the correct value or should it be higher or perhaps lower?
Why we changed our name to the MattCorc Podcast. Who is taking the most risk with the Amazon headquarters, Amazon or the local/state government? What is Waymo? The first autonomous ride hailing service is getting ready to launch in Arizona.
Moderna plans the biggest biotech IPO ever and we learn more about Amarin’s clinical study. Was mineral oil the best choice of placebo? Lessons we can learn from Amarin about D&O insurance.
I talk about how brokers use benchmarking to sell you more D&O insurance. Brokers take advantage of herd mentality so insurers buy more D&O than they need.
Cost and its importance are discussed. Minor differences in coverage can cause major headaches when you have a claim.
Happy national doughnut day! Fewer companies in the S&P are providing negative guidance. What does this mean? How CFOs are protecting their balance sheets in the event their manufacturing is disrupted.
Why is Aimmune (AIMT) up today? Is it because Halloween reminded investors how many types of candy have peanuts in them? A lesson on how to make sure you aren’t missing significant coverage gaps in your insurance program. Hint: I learned it from checking my kids Halloween candy.
How my first time swimming in a lap pool in years was a good metaphor for today’s market and some other interesting facts on the financial markets.
An overview of the President’s drug pricing proposal and what the new California sexual harassment law could mean for your insurance.
With biotech stocks sinking, the XBI just hit a 52 week low, and interest rates rising will we see an urgency for acquisitions to be done?
Quick post on why Insurance buying doesn’t need to be so abstract.
A ton was learned at the MWE life science deal making symposium and here I share that with you.
A synopsis of DeviceTalks Boston. Pathways to acquisition, hurdles that you might face and how to derisk your company to make it more appealing to investors and acquiring companies.
What can we learn from the alleged Chinese cyber espionage incident and how cyber insurance could respond.
I would love to hear whether people believe the pace of biotech IPOs will continue. Hear my thoughts and share yours at mattcorc.com.
Why D&O Insurance is expensive for life science companies and how the stage your company is in impacts pricing.
A client had a fire and $250,000 in product was destroyed. Undamaged condemned stock was valued at over $500,000 but there insurance did not cover it. Find out why that should never happen.
A recap of the Maryland Bio-Tech Conference that I recently attended.
A recap of the CFO Forum put on by the NJ Tech Council. The speaker was Jim Mastakas who was the CFO of Amneal when they merged with Impax Labs